Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ALK |
| Variant | negative |
| Impact List | unknown |
| Protein Effect | loss of function |
| Gene Variant Descriptions | ALK negative indicates a lack of expression of the ALK mRNA and/or protein. |
| Associated Drug Resistance | |
| Category Variants Paths |
ALK mutant ALK inact mut ALK negative |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03075553 | Phase II | Nivolumab | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Terminated | USA | 0 |
| NCT02663297 | Phase I | ATLCAR.CD30 cells | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | Active, not recruiting | USA | 0 |
| NCT03905135 | Phase I | Avelumab + rhIL-15 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | Completed | USA | 0 |